Bio-Techne Corporation, a global provider of life science tools, reagents and diagnostic products, announced the opening of a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom, further expanding the company's global capabilities to support the rapidly growing cell therapy market. The investment reflects Bio-Techne's commitment to helping therapy developers address one of the industry's most pressing challenges: establishing scalable, reproducible manufacturing processes that can support programs from early development through commercialization.
"As the cell therapy field continues to mature, success increasingly depends on the ability to manufacture therapies consistently and at scale," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Our investment in Bristol demonstrates Bio-Techne's commitment to providing customers with the GMP materials, manufacturing expertise, and supply chain reliability needed to accelerate development and ultimately bring transformative therapies to patients worldwide."
The Bristol expansion is the latest milestone in Bio-Techne's broader strategy to build a comprehensive manufacturing network supporting every stage of the cell therapy workflow. Together with the company's recombinant protein manufacturing operations in Minneapolis, Minnesota, its extensive GMP capabilities in St Paul, and its strategic relationship with Wilson Wolf Corporation, a leading manufacturer of cell culture devices including the widely adopted G-Rex® platform, Bio-Techne offers an increasingly integrated portfolio of GMP proteins, GMP small molecules, GMP cell media, custom manufacturing services, analytical solutions, and process development support. Collectively, these capabilities help customers transition seamlessly from research through clinical development and commercial production.